Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

116.50DKK
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
kr.116.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
116,904
52-wk High
kr.141.00
52-wk Low
kr.85.50

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.83
Market Cap(Mil.): kr.3,578.90
Shares Outstanding(Mil.): 30.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Zealand Pharma and Orbit Discovery enter into research collaboration

* REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION

Sep 07 2017

BRIEF-Zealand Pharma to present at Morgan Stanley Global Healthcare Conference

* REG-ZEALAND PHARMA TO PRESENT AT MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE IN NEW YORK ON SEPTEMBER 12, 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 05 2017

BRIEF-Zealand Pharma Q2 operating loss widens to DKK 94.8 mln

* H1 REVENUE OF DKK 88.4 MILLION/USD 13.6 MILLION (DKK 14.7 MILLION/USD 2.2 MILLION IN FIRST HALF OF 2016)

Aug 24 2017

BRIEF-Zealand Pharma partner starts Phase 1 trials for two novel treatments

* PHASE 1 TRIALS FOR TWO NOVEL TREATMENTS OF OBESITY AND/OR DIABETES INITIATED BY ZEALAND PARTNER BOEHRINGER INGELHEIM

Aug 22 2017

BRIEF-Zealand Pharma A/S sees IPO of upto 3.9 mln American depositary shares, representing 3.9 mln shares - SEC FILING

* Zealand Pharma A/S sees IPO of up to 3.9 million American depositary shares, representing 3.9 million shares - SEC filing

Aug 01 2017

BRIEF-Zealand reports Q2 royalty revenue of DKK 9.1 mln

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE SECOND QUARTER OF 2017

Jul 31 2017

BRIEF-Zealand Pharma files for U.S. IPO of up to $86.3 mln

* Zealand Pharma a/s files for u.s. Ipo of up to $86.3 million - sec filing

Jul 06 2017

BRIEF-Zealand Pharma: phase 2a trial results support development of dasiglucagon

* PHASE 2A TRIAL RESULTS SUPPORT DEVELOPMENT OF DASIGLUCAGON IN ILET PUMP SYSTEM FOR TYPE 1 DIABETES

Jun 22 2017

BRIEF-Zealand Pharma regains control of elsiglutide

* ZEALAND NOW HAS FULL RIGHTS TO DEVELOP PRODUCTS WITHIN CANCER-SUPPORTIVE CARE

Jun 12 2017

BRIEF-Zealand Pharma Phase 2 trial with dasiglucagon indicate rapid, effective increases in blood glucose

* SAID ON SATURDAY THAT THE RESULTS FROM PHASE 2 TRIAL WITH DASIGLUCAGON INTENDED FOR RESCUE TREATMENT INDICATE RAPID AND EFFECTIVE INCREASES IN BLOOD GLUCOSE IN ADULT TYPE 1 DIABETES PATIENTS WITH LOW BLOOD SUGAR

Jun 12 2017

Earnings vs. Estimates